Anglo-Scandinavian Cardiac Outcomes Trial; Post Trial Follow-Up Study - ASCOT-10

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-023875-24-GB

Enrollment

5450

Registered

2011-01-10

Start date

2011-02-23

Completion date

Unknown

Last updated

2016-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, cardiovascular disease

Interventions

Trade Name: Atorvastatin (Lipitor) Product Name: Atorvaststin Pharmaceutical Form: Tablet Trade Name: Atenolol Product Name: Atenolol Pharmaceutical Form: Trade Name: Bendroflumethiazide Product Na

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who participated in the original ASCOT study at the participating UK sites will be invited to take part in the current study. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: There are no exclusion criteria. Every living ASCOT patient is eligible.

Design outcomes

Primary

Measure	Time frame
Main Objective: The principal research objective is to see whether there are long-term differences between the study treatments used in the original ASCOT study (atenolol-based vs perindopril-based treatment on blood pressure lowering, and atorvastatin versus placebo treatment on cholesterol lowering) in terms of cardiovascular disease (heart attacks, strokes and death from cardiovascular disease). ;Secondary Objective: The secondary objectives are: 1.To find out how many people in the study population have developed diabetes since the end of ASCOT. 2.To find out, in patients who developed diabetes during the main ASCOT study, whether this has affected their long term cardiovascular health. 3.To see whether the variability of blood pressure recorded for individual patients during the ASCOT study can predict long term cardiovascular health. ;Primary end point(s): The primary outcome measure is a combined cardiovascular endpoint: cardiovascular mortality + non-fatal MI + non-fatal stroke.	—

Measure

Time frame

Main Objective: The principal research objective is to see whether there are long-term differences between the study treatments used in the original ASCOT study (atenolol-based vs perindopril-based treatment on blood pressure lowering, and atorvastatin versus placebo treatment on cholesterol lowering) in terms of cardiovascular disease (heart attacks, strokes and death from cardiovascular disease). ;Secondary Objective: The secondary objectives are: 1.To find out how many people in the study population have developed diabetes since the end of ASCOT. 2.To find out, in patients who developed diabetes during the main ASCOT study, whether this has affected their long term cardiovascular health. 3.To see whether the variability of blood pressure recorded for individual patients during the ASCOT study can predict long term cardiovascular health. ;Primary end point(s): The primary outcome measure is a combined cardiovascular endpoint: cardiovascular mortality + non-fatal MI + non-fatal stroke.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026